Search
Tanimite Medicine Provides Third Rock Ventures with Its Inaugural Clinical Candidate Molecule
3 day ago /
Read about 0 minute
Author：小编
On June 9, Tanimite Medicine made an announcement stating that its subsidiary, DynamiPeptide, had successfully handed over the inaugural clinical candidate drug molecule for a project developed in collaboration with Third Rock Ventures, a venture capital firm based in the United States. Remarkably, the project spanned less than 18 months from its inception to the identification of the candidate molecule, thereby prompting a milestone payment. Presently, the second joint project between the two entities has progressed into the lead compound optimization stage.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
